

Special Issue

Advances in Antitumor Molecular-Targeted Agents of Urological Cancers

Message from the Guest Editors

According to tumor malignancy statistics, the occurrence of urological cancers is continuously increasing in Western countries; this is mainly due to the increased life expectancy in these geographic areas, but other factors also contribute to this growth. An understanding of dysregulated pathways and the identification of potential biomarkers for the treatment of urological cancers have facilitated the identification of new targets and pathways for novel-targeted therapies, including immunomodulatory agents and agents that target angiogenesis, growth factor receptors, and epigenetic pathways. The aim of this Special Issue is to present recent advances in antitumor molecular-targeted agents in prostate, kidney, bladder, and testicular cancer, and to present clinical evidence of their use, whether alone or in combination.

Guest Editors

Dr. Maria Giuseppa Vitale

Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy

Dr. Roberto Sabbatini

Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/163604

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)